Owing to the vast target repertoire of RUNX1 and STAT3, both of them were reported to be critical for CML progression towards BC phase and development of imatinib resistance [26, 27], presenting physiologically challenging scenarios for CML treatment [2, 28, 29]. Here, RUNX1 is linked to breast cancer.